Supportive Care in Cancer,
Journal Year:
2024,
Volume and Issue:
33(1)
Published: Dec. 18, 2024
Abstract
Purpose
To
summarise
the
extent
and
type
of
evidence
in
relation
to
adverse
events
(AEs)
associated
with
use
cannabis-based
products
(CBP)
people
living
cancer.
Methods
The
Joanna
Briggs
Institute
(JBI)
methodology
for
scoping
reviews
was
applied.
A
search
performed
MEDLINE
(Ovid),
Embase
CINAHL
(EBSCOhost),
Scopus,
Web
Science
Core
Collections
AMED
(Ovid)
from
their
inception
7
May
2023.
Primary
studies
reporting
AEs
any
form
natural
or
synthetic
CBP
cancer
care
setting
location
were
included.
Results
One
hundred
fifty-two
included,
most
prevalent
being
randomised
controlled
trials
(RCTs)
(
n
=
61),
followed
by
non-randomised
26)
case
reports
23).
mainly
used
gastrointestinal,
liver,
peritoneal
98)
haematological
lymphoid
92),
primarily
manage
nausea
vomiting
78)
pain
37).
common
ingredients
combinations
THC
CBD
69),
47),
single
compounds
42)
16)
diverse
forms,
administration
routes
doses.
primary
methods
oral
94)
inhalation
54).
broad
range
reported;
related
nervous
system
118),
psychiatric
101)
gastrointestinal
81).
Diverse
patient
characteristics,
significant
under-reporting
low-quality
observed
many
studies.
Conclusions
More
rigorous
research
designs
that
prioritise
comprehensive,
standardised
are
required
fully
elucidate
safety
profile
care.
Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
17(3), P. 319 - 319
Published: March 1, 2025
Cannabis
is
the
most
commonly
used
illicit
substance
worldwide.
Recent
years
have
seen
an
increase
in
cannabis
consumption,
and
with
new
approvals
therapeutic
indications,
there
are
challenges
minimizing
risks
interactions
between
cannabis-based
products,
prescription
drugs,
other
approved
substances
of
abuse.
Thus,
identifying
enzymes
metabolizing
cannabinoid
drugs
their
relationship
crucial
for
understanding
potential
effects
simultaneous
use.
This
article
offers
a
comprehensive
review
pharmacokinetic
as
well
It
also
compiles
existing
evidence
these
describes
clinical
outcomes
associated
inhibition
or
induction
various
enzymes.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(11), P. 5749 - 5749
Published: May 25, 2024
Neurological
disorders
present
a
wide
range
of
symptoms
and
challenges
in
diagnosis
treatment.
Cannabis
sativa,
with
its
diverse
chemical
composition,
offers
potential
therapeutic
benefits
due
to
anticonvulsive,
analgesic,
anti-inflammatory,
neuroprotective
properties.
Beyond
cannabinoids,
cannabis
contains
terpenes
polyphenols,
which
synergistically
enhance
pharmacological
effects.
Various
administration
routes,
including
vaporization,
oral
ingestion,
sublingual,
rectal,
provide
flexibility
treatment
delivery.
This
review
shows
the
efficacy
managing
neurological
such
as
epilepsy,
neurodegenerative
diseases,
neurodevelopmental
disorders,
psychiatric
painful
pathologies.
Drawing
from
surveys,
patient
studies,
clinical
trials,
it
highlights
alleviating
symptoms,
slowing
disease
progression,
improving
overall
quality
life
for
patients.
Understanding
mechanisms
can
open
up
possibilities
using
this
plant
individual
needs.
Frontiers in Pharmacology,
Journal Year:
2024,
Volume and Issue:
15
Published: May 22, 2024
The
recent
exponential
increase
in
legalized
medical
and
recreational
cannabis,
development
of
cannabis
programs,
production
unregulated
over-the-counter
products
(e.g.,
cannabidiol
(CBD)
oil,
delta-8-tetrahydrocannabinol
(delta-8-THC)),
has
the
potential
to
create
unintended
health
consequences.
major
cannabinoids
(delta-9-tetrahydrocannabinol
cannabidiol)
are
metabolized
by
same
cytochrome
P450
(CYP)
enzymes
that
metabolize
most
prescription
medications
xenobiotics
(CYP3A4,
CYP2C9,
CYP2C19).
As
a
result,
we
predict
there
will
be
instances
drug-drug
interactions
for
adverse
outcomes,
especially
with
narrow
therapeutic
index.
We
conducted
systematic
review
all
years
2023
identify
real
world
reports
documented
cannabinoid
medications.
limited
our
search
set
list
predicted
indices
may
produce
drug
reactions
(ADRs).
Our
team
screened
4,600
selected
151
full-text
articles
assess
inclusion
exclusion
criteria.
investigation
revealed
31
which
altered
pharmacokinetics
and/or
produced
events.
These
involved
16
different
Narrow
Therapeutic
Index
(NTI)
medications,
under
six
classes,
889
individual
subjects
603
cannabis/cannabinoid
users.
Interactions
between
cannabis/cannabinoids
warfarin,
valproate,
tacrolimus,
sirolimus
were
widely
reported
pose
greatest
risk
patients.
Common
ADRs
included
bleeding
risk,
mental
status,
difficulty
inducing
anesthesia,
gastrointestinal
distress.
Additionally,
identified
18
(58%)
clinicians
uncovered
an
unexpected
serum
level
prescribed
drug.
quality
pharmacokinetic
evidence
each
report
was
assessed
using
internally
developed
ten-point
scale.
Drug-drug
likely
amongst
use
common
CYP450
systems.
findings
highlight
need
healthcare
providers
patients/care-givers
openly
communicate
about
prevent
To
end,
have
free
online
tool
(www.CANN-DIR.psu.edu)
help
Frontiers in Artificial Intelligence,
Journal Year:
2025,
Volume and Issue:
8
Published: Feb. 20, 2025
Chronic
pain
affects
approximately
30%
of
the
global
population,
posing
a
significant
public
health
challenge.
Despite
their
widespread
use,
traditional
pharmacological
treatments,
such
as
opioids
and
NSAIDs,
often
fail
to
deliver
adequate,
long-term
relief
while
exposing
patients
risks
addiction
adverse
side
effects.
Given
these
limitations,
medical
cannabis
has
emerged
promising
therapeutic
alternative
with
both
analgesic
anti-inflammatory
properties.
However,
its
clinical
efficacy
is
hindered
by
high
interindividual
variability
in
treatment
response
elevated
dropout
rates.
A
comprehensive
dataset
integrating
genetic,
clinical,
information
was
compiled
from
542
Caucasian
undergoing
cannabis-based
for
chronic
pain.
machine
learning
(ML)
model
developed
validated
predict
therapy
dropout.
To
identify
most
influential
factors
driving
dropout,
SHapley
Additive
exPlanations
(SHAP)
analysis
performed.
The
random
forest
classifier
demonstrated
robust
performance,
achieving
mean
accuracy
80%
maximum
86%,
an
AUC
0.86.
SHAP
revealed
that
final
VAS
scores
THC
dosages
were
predictors
strongly
correlated
increased
likelihood
discontinuation.
In
contrast,
baseline
benefits,
CBD
dosages,
CC
genotype
rs1049353
polymorphism
CNR1
gene
associated
improved
adherence.
Our
findings
highlight
potential
ML
pharmacogenetics
personalize
therapies,
improving
adherence
enabling
more
precise
management
This
research
paves
way
development
tailored
strategies
maximize
benefits
minimizing
Medical Science of Ukraine (MSU),
Journal Year:
2025,
Volume and Issue:
21(1), P. 158 - 166
Published: March 31, 2025
Background.
Neuropathic
pain
is
a
debilitating
syndrome
that
underlies
phantom
pain,
in
particular
-
due
to
combat
trauma.
Phantom
neuropathic
affects
45-85%
of
patients
who
have
undergone
limb
amputations
or
spinal
cord
injury.
Less
than
half
manage
achieve
significant
relief
with
pregabalin,
gabapentin,
duloxetine
and
tricyclic
antidepressants.
Taking
opioid
drugs
accompanied
by
many
undesirable
side
effects.
Aim:
review
current
data
on
the
possibility
using
cannabinoids
treatment
chronic
pain.
Materials
methods.
Analysis
presented
PubMed,
keywords
“neuropathic
pain”,
“cannabinoids”,
“efficacy”,
“safety”.
Results.
The
bioavailability
main
psychoactive
component
marijuana,
delta-9-tetrahydrocannabinol
(THC),
orally
only
6%
(due
intensive
presystemic
metabolism
intestinal
wall
influence
drug
transporters
P-gp
BCRP),
while
when
smoked
it
25%,
inhaled
10–35%.
pharmacokinetics
another
component,
cannabidiol
(CBD),
do
not
differ
significantly.
Therefore,
cannabis
inhaled,
acute
relieved,
provides
long-lasting
effect,
which
advisable
use
for
constant
THC/CBD
ratio
gradual
increase
its
dose
are
great
importance.
An
anonymous
survey
227
traumatic
injury
showed
87.9%,
reduced
intensity
more
30%.
majority
participants
(83.3%)
indicated
they
had
replaced
their
analgesic
medications
(including
opioids
gabapentinoids)
cannabis.
number
needed
treat
30%
reduction
2.9-3.2
medium
low
doses
Conclusion.
Medical
preparations
proven
effectiveness
correction
corresponds
opioids,
risk
adverse
reactions
significantly
lower.
It
necessary
take
into
account
features
clinical
course
disease
choose
route
administration,
initial
rate
titration
therapy
minimize
Chemico-Biological Interactions,
Journal Year:
2024,
Volume and Issue:
394, P. 110988 - 110988
Published: April 3, 2024
Epilepsy
is
a
neurological
disorder
characterized
by
overstimulation
of
neurotransmitters
and
uncontrolled
seizures.
Current
medications
for
epilepsy
result
in
adverse
effects
or
insufficient
seizure
control,
highlighting
the
necessity
to
develop
alternative
therapies.
Cannabidiol
(CBD),
derived
from
cannabis
plants,
has
been
popularly
explored
as
an
alternative.
CBD
shown
have
anti-convulsivatng
muscle-relaxing
properties,
which
used
patients
with
promising
results.
research
explores
varying
dosages
either
adult
paediatric
patients,
little
no
comparison
between
two
populations.
In
this
review,
we
aim
at
consolidating
data
comparing
effect
pharmacokinetic
properties
across
these
patient
When
absorption,
there
was
show
differences
patients.
Similarly,
limited
information
available
distribution
CBD,
but
higher
volume
found
population.
From
metabolism
perspective,
population
had
greater
success
rate
when
treated
drug
compared
elimination,
were
clear
distinctions
clearance
The
drug's
half-life
highly
variable
both
populations,
paediatrics
having
lower
range
than
adults.
summary,
more
significant
reduction
severity
seizures
upon
treatment.
complexity
operates
highlights
need
further
studies
compound
understand
why
occur
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(22), P. 12453 - 12453
Published: Nov. 20, 2024
Autism
spectrum
disorder
(ASD)
is
a
neurological
disease
and
lifelong
condition.
The
treatment
gap
in
ASD
has
led
to
growing
interest
alternative
therapies,
particularly
phytocannabinoids,
which
are
naturally
present
Biomedicines,
Journal Year:
2023,
Volume and Issue:
11(7), P. 1776 - 1776
Published: June 21, 2023
Conventional
therapy
options
for
chronic
pain
are
still
insufficient
and
patients
most
frequently
request
alternative
medical
treatments,
such
as
cannabis.
Although
clinical
evidence
supports
the
use
of
cannabis
pain,
very
little
is
known
about
efficacy,
dosage,
administration
methods,
or
side
effects
widely
used
accessible
products.
A
possible
solution
could
be
given
by
pharmacogenetics,
with
identification
several
polymorphic
genes
that
may
play
a
role
in
pharmacodynamics
pharmacokinetics
Based
on
these
findings,
data
from
treated
genotyped
candidate
(single-nucleotide
polymorphism:
SNP)
were
collected,
integrated,
analyzed
through
machine
learning
(ML)
model
to
demonstrate
reduction
intensity
closely
related
gene
polymorphisms.
Starting
patient's
method
therapeutic
process,
avoiding
ineffective
results
occurrence
effects.
Our
findings
suggest
ML
prediction
has
potential
positively
influence
pharmacogenomics
facilitate
translation
genomic
profile
into
useful
knowledge.
British Journal of Cancer,
Journal Year:
2023,
Volume and Issue:
130(1), P. 19 - 30
Published: Oct. 26, 2023
Abstract
The
side
effects
of
cancer
therapy
continue
to
cause
significant
health
and
cost
burden
the
patient,
their
friends
family,
governments.
A
major
barrier
in
way
which
these
are
managed
is
highly
siloed
mentality
that
results
a
fragmented
approach
symptom
control.
Increasingly,
it
appreciated
many
symptoms
manifestations
common
underlying
pathobiology,
with
changes
gastrointestinal
environment
key
driver
for
sequelae.
Breakdown
mucosal
(mucositis)
early
effect
anti-cancer
agents,
known
contribute
(in
part)
range
burdensome
such
as
diarrhoea,
nausea,
vomiting,
infection,
malnutrition,
fatigue,
depression,
insomnia.
Here,
we
outline
rationale
how,
based
on
its
already
documented
microenvironment,
medicinal
cannabis
could
be
used
control
mucositis
prevent
constellation
associated.
We
will
provide
brief
update
current
state
evidence
care
potential
benefits
(and
challenges)
using
during
active
therapy.
